1101
|
Asquith KL, Kitchener AL, Kay DJ. Immunisation of the male tammar wallaby (Macropus eugenii) with spermatozoa elicits epididymal antigen-specific antibody secretion and compromised fertilisation rate. J Reprod Immunol 2006; 69:127-47. [PMID: 16380166 DOI: 10.1016/j.jri.2005.08.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2005] [Revised: 08/23/2005] [Accepted: 08/31/2005] [Indexed: 11/20/2022]
Abstract
Immunocontraception has been proposed as an effective and humane means of controlling overabundant kangaroo populations in Australia. We have examined the feasibility of using a sperm-based vaccine for this purpose using a model macropod species, the tammar wallaby (Macropus eugenii). This study has demonstrated immunocontraception in a marsupial species following immunisation of males with homologous spermatozoa. Serum anti-sperm IgG titres were associated with a significant reduction in fertilisation rates following mating with superovulated female wallabies. Antigen-specific IgG penetrated the reproductive tract at the rete testis and bound spermatozoa in vivo. IgG was detected bound to the acrosome and midpiece regions of both epididymal and ejaculated spermatozoa. The absence of adverse testicular pathology and sperm movement effects suggests that contraception may have been achieved by antibody-mediated blocking of sperm surface antigens essential for fertilisation. This study demonstrates that a contraceptive vaccine targeting sperm antigens has potential for fertility control in male macropods.
Collapse
Affiliation(s)
- Kelly L Asquith
- Cooperative Research Centre for Conservation and Management of Marsupials, School of Environmental and Life Sciences, University of Newcastle, NSW, Australia
| | | | | |
Collapse
|
1102
|
Petrunov B, Marinova S, Markova R, Nenkov P, Nikolaeva S, Nikolova M, Taskov H, Cvetanov J. Cellular and humoral systemic and mucosal immune responses stimulated in volunteers by an oral polybacterial immunomodulator "Dentavax". Int Immunopharmacol 2006; 6:1181-93. [PMID: 16714223 DOI: 10.1016/j.intimp.2006.02.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2005] [Revised: 11/21/2005] [Accepted: 02/28/2006] [Indexed: 11/17/2022]
Abstract
The oral polybacterial immunomodulator Dentavax (D), composed of killed cells from Klebsiella pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Candida albicans and Lactobacillus acidophilus and their lysates was created for immunoprophylaxis and therapy of oral mucosa and parodont inflammations. The stimulating effect of the preparation was evaluated in twelve volunteers immunized for 10 consecutive days. On days 7, 14, 21, 28 and 49 after the last immunization peripheral blood (PB) lymphocyte subsets, T lymphocyte activation and PB phagocytic activity, were studied by flow cytometry. PB lymphocyte proliferative responses to PHA, rIL-2, LPS and D were evaluated radiometrically. The production of TNF-alpha in supernatants of in vitro stimulated lymphocytes and specific IgA, IgM and IgG antibodies in serum and saliva was determined by ELISA. Ultrastructural morphologic changes in T and B lymphocyte populations were also investigated. Although no significant changes in the levels of basic lymphocyte subsets were detected, the early/late (CD57+/CD57-) CD8 T effectors ratio was increased at the end of the studied period, as were the percentage of PHA-responding (CD69+) T cells and PB phagocytizing cells. The most prominent lymphoprolipherative responses were measured upon costimulation with LPS+D and PHA+D on day 21. Electron-microscopic studies demonstrated a significant effect of D on both T and B cell activity. TNF-alpha concentration increased progressively from day 7 till the end of the investigation. Maximal concentrations were observed after stimulation with D and LPS. An increased level of specific salivary and serum antibodies against the components of D was found, with highest levels between days 7 and 21. Specific secretory IgA predominated in saliva as compared to IgM and IgG. Our results demonstrate the stimulating effect of Dentavax on PB lymphocyte functional activity and the specific humoral systemic and mucosal immunity.
Collapse
Affiliation(s)
- Bogdan Petrunov
- National Center of Infectious and Parasitic Diseases (NCIPD), Sofia, Bulgaria
| | | | | | | | | | | | | | | |
Collapse
|
1103
|
Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B. Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin Drug Deliv 2006; 3:87-95. [PMID: 16370942 DOI: 10.1517/17425247.3.1.87] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
This paper reviews the developments in noninvasive methods of drug delivery, with a focus on the delivery of vaccines via the respiratory tract. Recent results indicate that the respiratory system, and the nasal mucosa in particular, provide a valuable target site for immunisation against respiratory and mucosal pathogens. Vaccine delivery via the nasal and pulmonary routes each present distinct sets of performance requirements. Current delivery systems in development for both routes are reviewed herein. The storage and respiratory delivery of drugs and vaccines in powder form has been shown to provide improved stability and extended retention time in the respiratory mucosa. These features, in addition to the noninvasive nature of respiratory delivery, can provide benefits to public health vaccination campaigns, facilitating mass vaccination without the high cost of maintaining cold-chain storage.
Collapse
|
1104
|
Abstract
The vast surfaces of the gastrointestinal, respiratory, and genitourinary tracts represent major sites of potential attack by invading micro-organisms. Immunoglobulin A (IgA), as the principal antibody class in the secretions that bathe these mucosal surfaces, acts as an important first line of defence. IgA, also an important serum immunoglobulin, mediates a variety of protective functions through interaction with specific receptors and immune mediators. The importance of such protection is underlined by the fact that certain pathogens have evolved mechanisms to compromise IgA-mediated defence, providing an opportunity for more effective invasion. IgA function may also be perturbed in certain disease states, some of which are characterized by deposition of IgA in specific tissues. This review details current understanding of the roles played by IgA in both health and disease.
Collapse
Affiliation(s)
- Jenny M Woof
- Division of Pathology and Neuroscience, University of Dundee Medical School, Ninewells Hospital, UK.
| | | |
Collapse
|
1105
|
Dell K, Koesters R, Linnebacher M, Klein C, Gissmann L. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 2006; 24:2238-47. [PMID: 16455165 DOI: 10.1016/j.vaccine.2005.11.060] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2005] [Revised: 10/26/2005] [Accepted: 11/10/2005] [Indexed: 11/24/2022]
Abstract
Prophylactic immunization against human papillomaviruses (HPVs) aims preferentially at the generation of antibodies, which are directed against the virus capsid proteins. DNA-free virus-like particles or their pentameric subunits, the capsomeres represent suitable antigens. Here we investigated if anti-HPV16 L1 specific antibodies and L1-specific CTL induced by intranasal immunization with capsomeres in sera and vaginal washings of C57Bl6 mice can be enhanced by co-application of the non-toxic cholera toxin adjuvants CTA1-D2D1 or CTB. We found that CTA1-D2D1 elevated L1-specific serum IgG antibodies in a dose-dependent manner and both CTA1-D2D1 and CTB significantly increased L1-specific IgA antibody levels in the vaginal lumen. Furthermore, CTA1-D2D1 and CTB enhanced L1-specific CTL responses.
Collapse
Affiliation(s)
- Kerstin Dell
- Deutsches Krebsforschungszentrum, Angewandte Tumorvirologie, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany.
| | | | | | | | | |
Collapse
|
1106
|
Desselberger U. Fighting infection: challenges and recent advances in microbiology. Future Virol 2006. [DOI: 10.2217/17460794.1.2.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- Ulrich Desselberger
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Molecular Immunology, Padriciano 99, 34012 Trieste, Italy
| |
Collapse
|
1107
|
Heyderman RS, Davenport V, Williams NA. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines. Trends Microbiol 2006; 14:120-4. [PMID: 16469496 DOI: 10.1016/j.tim.2006.01.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2005] [Revised: 12/20/2005] [Accepted: 01/23/2006] [Indexed: 10/25/2022]
Abstract
Candidate Neisseria meningitidis serogroup B vaccines that are based on outer-membrane vesicles induce protective immunity in adults but provide neither crossprotection for infants nor long-lasting immunity. We suggest that this lack of vaccine efficacy is not solely because the best antigens are yet to be identified but also results from inappropriate programming of the immune response. Natural carriage of N. meningitidis and related bacteria leads to the development of protective immunity both at the mucosal surface and in the circulation. We propose that vaccine strategies that mimic this natural immunization process would better-optimize vaccine-induced protective immunity. Thus, mucosal immunization before a systemic booster vaccination could provide the solution and reduce the necessity for multiple injections to achieve immunity.
Collapse
Affiliation(s)
- Robert S Heyderman
- Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, UK.
| | | | | |
Collapse
|
1108
|
Sleator RD, Hill C. Patho-biotechnology: using bad bugs to do good things. Curr Opin Biotechnol 2006; 17:211-6. [PMID: 16459072 DOI: 10.1016/j.copbio.2006.01.006] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2005] [Revised: 11/16/2005] [Accepted: 01/20/2006] [Indexed: 12/27/2022]
Abstract
Pathogenic bacteria have evolved sophisticated strategies to overcome host defences, to interact with the immune system and to interfere with essential host systems. We coin the term 'patho-biotechnology' to describe the exploitation of these valuable traits in biotechnology, medicine and food. This approach shows promise for the development of novel vaccine and drug delivery systems, as well as for the design of more technologically robust and effective probiotic cultures with improved biotechnological and clinical applications. The genetic tractability of Listeria monocytogenes, the availability of the complete genome sequence of this intracellular pathogen, its ability to cope with stress, and its ability to traverse the gastrointestinal tract and induce a strong cellular immune response make L. monocytogenes an ideal model organism for demonstrating the patho-biotechnology concept.
Collapse
Affiliation(s)
- Roy D Sleator
- Department of Microbiology & Alimentary Pharmabiotic Centre, University College, Cork, Ireland
| | | |
Collapse
|
1109
|
Han IK, Kim YB, Kang HS, Sul D, Jung WW, Cho HJ, Oh YK. Thermosensitive and mucoadhesive delivery systems of mucosal vaccines. Methods 2006; 38:106-11. [PMID: 16414271 DOI: 10.1016/j.ymeth.2005.10.003] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2005] [Accepted: 10/27/2005] [Indexed: 11/25/2022] Open
Abstract
Mucosal vaccination is emerging as a potential administration route for eliciting antigen-specific mucosal and systemic immunogenicity. Most mucosal vaccines have been administered in a phosphate-buffered saline vehicle that may limit the exposure of antigens to the mucosal surfaces and result in poor immunogenicity. To improve the potency of the mucosal vaccines, we have developed mucosal vaccine delivery systems that might prevent leakage and increase retention of vaccines on mucosal surfaces. Thermosensitive polymers have been used to reduce the leakage problems of nasal or vaginal vaccines, while mucoadhesive polymers have been employed to increase the mucosal contact of the vaccines. Here, we describe the formulation and delivery methods of mucosal vaccines using thermosensitive and mucoadhesive polymers.
Collapse
Affiliation(s)
- In-Kwon Han
- MyGene Bioscience Institute, Kangnam-gu, Seoul, Republic of Korea.
| | | | | | | | | | | | | |
Collapse
|
1110
|
Ferro VA, Carter KC. Mucosal immunisation: Successful approaches to targeting different tissues. Methods 2006; 38:61-4. [PMID: 16442812 DOI: 10.1016/j.ymeth.2005.11.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2005] [Accepted: 11/16/2005] [Indexed: 11/20/2022] Open
|
1111
|
Mann JFS, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, Ferro VA. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 2006; 38:90-5. [PMID: 16414269 DOI: 10.1016/j.ymeth.2005.11.002] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/23/2005] [Indexed: 11/23/2022] Open
Abstract
Protein antigens administered via the oral route are exposed to a hostile environment in the gastrointestinal tract, consisting of digestive enzymes and a range of pH (1-7.5). Using a delivery system can afford protection to entrapped components against degradation and permit delivery of antigen to the cells responsible for generating local and systemic immune responses. In this comparative study, mice were immunised orally with tetanus toxoid (40 or 200 microg dose/mouse, four doses in total) entrapped in non-ionic surfactant vesicles formulated with bile salts (bilosomes). The higher entrapped dose (BV-TT, 200 microg) induced IgG1 by study week 3 to similar levels to those observed with subcutaneous un-entrapped TT at the lower (<50 microg) dose. However, both bilosome formulations (BV-TT, low, and high doses), though not un-entrapped TT, caused a rise in the numbers of IgA positive plasma cells observed in the small intestine, primarily in the first 15 cm of the small intestine.
Collapse
Affiliation(s)
- Jamie F S Mann
- Department of Immunology, Strathclyde Institute for Biomedical Sciences, John Arbuthnott Building, University of Strathclyde, Glasgow G4 0NR, UK
| | | | | | | | | | | | | |
Collapse
|
1112
|
Lavelle EC. Lectins and microparticles for enhanced oral vaccination. Methods 2006; 38:84-9. [PMID: 16406570 DOI: 10.1016/j.ymeth.2005.09.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2005] [Accepted: 09/16/2005] [Indexed: 12/25/2022] Open
Abstract
Oral administration is an attractive means of vaccination since it alleviates the need for injection and trained personnel. Furthermore, effective oral vaccination induces immune responses locally in the gastrointestinal tract, the site of colonisation and infection by many pathogens. However, since most proteins and peptides are degraded in the gut, do not interact specifically with the epithelium, or induce strong immune responses, this route of delivery is generally inefficient. Two of the most promising potential approaches are the use of lectins to target vaccines to the epithelium and the association of vaccines with biodegradable microparticles. This paper describes methods to assess the stability of vaccines and targeting molecules in the gastrointestinal tract, interaction with the mucosa, uptake into internal organs and induction of mucosal antibody responses.
Collapse
Affiliation(s)
- E C Lavelle
- Adjuvant Research Group, Department of Biochemistry, Trinity College, Dublin 2, Ireland.
| |
Collapse
|
1113
|
Abstract
Most current immunization procedures make use of needles and syringes for vaccine administration. With the increase in the number of immunizations that children around the world routinely receive, health organizations are beginning to look for safer alternatives that reduce the risk of cross-contamination that arises from needle reuse. This article focuses on contemporary developments in needle-free methods of immunization, such as liquid-jet injectors, topical application to the skin, oral pills and nasal sprays.
Collapse
Affiliation(s)
- Samir Mitragotri
- Department of Chemical Engineering, University of California, Santa Barbara, California 93106, USA.
| |
Collapse
|
1114
|
Santana MA, Esquivel-Guadarrama F. Cell biology of T cell activation and differentiation. INTERNATIONAL REVIEW OF CYTOLOGY 2006; 250:217-74. [PMID: 16861067 DOI: 10.1016/s0074-7696(06)50006-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
T cells are major components of the adaptive immune system. They can differentiate into two different populations of effector cells-type one and type two-and may also become tolerant. T cells respond to immune challenges by interacting with antigen-presenting cells of the innate immune system. These latter cells can identify the nature of any immune challenge and initiate adaptive immune responses. Dendritic cells are the most important antigen-presenting cells in the body. The T cell recognizes both peptides associated with MHC molecules on the antigen-presenting cells and also other molecules in a complex structure known as an immunological synapse. The nature of the antigen, the cytokine environment, and other molecules on the dendritic cell surface instruct the T cells as to the response required. A better understanding of the biology of T cell responses offers the prospect of more effective therapeutic interventions.
Collapse
Affiliation(s)
- María Angélica Santana
- Faculty of Sciences, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
| | | |
Collapse
|
1115
|
De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006; 24:544-51. [PMID: 16169634 DOI: 10.1016/j.vaccine.2005.08.061] [Citation(s) in RCA: 90] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2005] [Accepted: 08/16/2005] [Indexed: 10/25/2022]
Abstract
Mucosal vaccination requires effective and safe adjuvants. We have evaluated the non-toxic adjuvant CTA1-DD for mucosal vaccination against influenza. CTA1-DD contains the enzymatically active CTA1 subunit of cholera toxin (CT) genetically fused to a gene encoding a dimer of the D-fragment from Staphylococcus aureus protein A. CTA1-DD only binds to Ig-receptor carrying cells of the immune system. Nasal administration of the universal influenza vaccine M2e-HBc in combination with CTA1-DD completely protected mice from a potentially lethal infection and significantly reduced morbidity. Sera of mice immunized with M2e-HBc + CTA1-DD revealed IgG subclass profiles consistent with an enhanced Th1-type immunity. When the vaccine was administered intraperitoneally, the adjuvant improved the M2e antibody titer in circulation, but did not significantly reduce the morbidity.
Collapse
Affiliation(s)
- Marina De Filette
- DMBR, Ghent University-VIB, FSVM-Building, Technologiepark 927, B-9052 Ghent (Zwijnaarde), Belgium
| | | | | | | | | | | | | | | |
Collapse
|
1116
|
Abstract
The majority of infections initiate their departure from a mucosal surface, such as Human immunodeficiency virus (HIV), a sexually transmitted virus. Therefore, the induction of mucosal immunity is a high priority in the development of vaccines against mucosal pathogens. The selection of an appropriate antigen delivery system is necessary to induce an efficient mucosal immune response. Poxvirus vectors have been the most intensively studied live recombinant vector, and numerous studies have demonstrated their ability to induce mucosal immune responses against foreign expressed antigens. Previous studies have demonstrated that recombinants based on the attenuated modified vaccinia virus Ankara (MVA) vector were effective in inducing protective responses against different respiratory viruses, such as influenza and respiratory syncytial virus, following immunization via mucosal routes. Recent studies performed in the murine and macaque models have shown that recombinant MVA (rMVA) does not only stimulate HIV-specific immunity in the genital and rectal tracts following mucosal delivery, but can also control simian/human immunodeficiency viraemia and disease progression. In addition, a prime-boost vaccination approach against tuberculosis emphasized the importance of the intranasal rMVA antigen delivery to induce protective immunity against Mycobacterium tuberculosis. The aim of this review is to summarize the studies employing recombinant poxviruses, specifically rMVA as a mucosal delivery vector. The results demonstrate that rMVAs can activate specific immune responses at mucosal surfaces, and encourage further studies to characterize and improve the MVA mucosal immunogenicity of poxvirus vectors.
Collapse
Affiliation(s)
- M Magdalena Gherardi
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, CSIC, Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
- National Reference Center for AIDS, Department of Microbiology, School of Medicine, University of Buenos Aires, Paraguay 2155 piso 11 (C1121ABG), Buenos Aires, Argentina
| | - Mariano Esteban
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, CSIC, Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
| |
Collapse
|
1117
|
Brayden DJ, Jepson MA, Baird AW. Keynote review: Intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov Today 2005; 10:1145-57. [PMID: 16182207 DOI: 10.1016/s1359-6446(05)03536-1] [Citation(s) in RCA: 148] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Specialized M cells in the follicle-associated epithelium of intestinal Peyer's patches serve as portals for diverse particulates. Following antigen handover to dome lymphocytes, a protective mucosal antibody secretion ensues. One approach to oral vaccine delivery is to mimic the entry pathways of pathogens via M cells. The paucity of human tissue for in vitro investigation has hampered the discovery of M-cell pathogen receptors; however an in vitro human M like-cell culture model displays many expected phenotypic features. Comparative studies using microarrays reveal several novel M-cell surface receptors that could be used to potentially target orally delivered antigens.
Collapse
Affiliation(s)
- David J Brayden
- Faculty of Veterinary Medicine and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland.
| | | | | |
Collapse
|
1118
|
Niedergang F, Kweon MN. New trends in antigen uptake in the gut mucosa. Trends Microbiol 2005; 13:485-90. [PMID: 16099657 DOI: 10.1016/j.tim.2005.08.001] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2005] [Revised: 07/15/2005] [Accepted: 08/03/2005] [Indexed: 01/22/2023]
Abstract
The mucosa represents a large surface of the human body that is in contact with the external environment. Mucosal tissues are colonized by an extremely dense and diverse micro flora of commensal bacteria, which compete with the growth of pathogenic strains. The mucosal sites continuously sample foreign material via specific cells, such as M cells and dendritic cells. Many new ways of antigen uptake have been described recently, especially by M cells and dendritic cells in the intestine. Depending on various factors, antigen presentation in the mucosa can lead to tolerance or initiation of an immune response. Mucosal vaccine strategies will certainly require eliciting specific antigen uptake because this initial step has a crucial role in controlling the outcome of immune responses.
Collapse
Affiliation(s)
- Florence Niedergang
- Département de Biologie Cellulaire, Institut Cochin, CNRS UMR8104, INSERM U567, Université Paris 5, Paris, France.
| | | |
Collapse
|